Phaseline

Targets › RIG1

RIG1 (Phospholipase A and acyltransferase 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.

Exhibits both phospholipase A1/2 and acyltransferase activities. Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids. (UniProt, Q9UL19)

Open in Phaseline: the race on RIG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Adilia HormigoPoly-ICLC (Hiltonol®)
Toll-like receptor 3 (TLR3) agonist and RIG-I-like receptor agonist - immune adjuvant
TLR3, RIG1Phase 1GlioblastomaMay 2029

Conditions

Glioblastoma (1)

Modalities

mixed (1)

Companies

Adilia Hormigo (1)

Related targets

TLR3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.